What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?  

I would offer metastasis-directed therapy with SBRT or if necessary based on site, hypofractionated (8-15 fractions) RT to oligoprogressive disease in this setting which we now have Phase 2 randomized data to support due to the nice work of Dr. @Tsai and her team in the CURB trial. Patients with 1-5...

First I should acknowledge that there is still a lack of consensus on the definition of oligoprogressive disease, and the definition of “second-line” could mean chemo after anti-PD(L)1, anti-PD-(L)1 after chemo, or post-chemoIO treatment. Generally, for patients with a predominant system...